This excerpt taken from the TPTX 8-K filed Jun 17, 2008.
Please indicate compliance status by circling Yes/No under Complies column.
SCHEDULE OF EXCEPTIONS
Permitted Indebtedness (Section 1.1)
Permitted Investments (Section 1.1)
Permitted Liens (Section 1.1)
Permitted Transfers (Section 1.1)
See Annex I attached hereto.
Invested Collateral (Section 5.3)
Borrower maintains a balance in certain accounts located in Belgium in the ordinary course of business.
Prior Names (Section 5.5)
TorreyPines Therapeutics, Inc.
Litigation (Section 5.6)
Several lawsuits were filed against us in February 2005 in the U.S. District Court for the Southern District of New York asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act and Rule 10b-5 thereunder on behalf of a class of purchasers of our common stock during the period from June 26, 2003, through and including February 4, 2005, referred to as the class period. Dr. Marvin S. Hausman, M.D., a former director and our former Chief Executive Officer, and Dr. Gosse B. Bruinsma, M.D., also a former director and our former Chief Executive Officer, were also named as defendants in the lawsuits. These actions were consolidated into a single class action lawsuit in January 2006. On April 10, 2006, the class action plaintiffs filed an amended consolidated complaint. We filed our answer to that complaint on May 26, 2006. Our motion to dismiss the consolidated amended complaint was filed on May 26, 2006 and was submitted to the court for a decision in September 2006. The motion to dismiss is pending.
The class action plaintiffs allege generally that our Phase III phenserine development program was subject to alleged errors of design and execution which resulted in the failure of the first Phase III phenserine trial to show efficacy. Plaintiffs allege the defendants failure to disclose the alleged defects resulted in the artificial inflation of the price of our shares during the class period.
There is also a shareholder derivative suit pending in New York Supreme Court, New York County, against our current and former directors and officers. The named defendants are Marvin S. Hausman, M.D., Gosse B. Bruinsma, M.D., S. Colin Neill, Louis G. Cornacchia, Steven H. Ferris, Ph.D., Gerard J. Vlak, Ralph Snyderman, M.D. and Michael A. Griffith. Defendants are alleged to have breached their duties to the company and misused inside information regarding clinical trials of phenserine. This action has been stayed pending further developments in the federal class action.
Inbound Licenses (Section 5.12)
Annex I to the Schedule of Exceptions
1. The Companys Gamma Secretase Modulator (GSM) Program, including, without limitation, patent 7,244,739 issued on July 17, 2007 and any other patents, patent applications, trademarks, trade names, service marks, copyrights, technology, trade secrets, proprietary information, know-how and processes relating to such program.
2. The Companys Alzheimers disease genetics program, including, without limitation, any patents, patent applications, trademarks, trade names, service marks, copyrights, technology, trade secrets, proprietary information, know-how and processes relating to such program.